NUCALA is for the:

- add-on maintenance treatment of patients 6+ with SEA. Not for acute bronchospasm or status asthmaticus.
- add-on maintenance treatment of CRSwNP in patients 18+ with inadequate response to nasal corticosteroids.
- treatment of adult patients with EGPA.
- treatment of patients aged 12+ with HES for ≥6 months without an identifiable non-hematologic secondary cause.

Important Safety Information

CONTRAINDICATIONS
NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

Please see Brief Summary of Prescribing Information for NUCALA on the following pages.
Visit **Nucale4EOS.com to learn more**

**Important Safety Information (cont’d)**

**WARNINGS AND PRECAUTIONS**

**Hypersensitivity Reactions**

Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). If a hypersensitivity reaction occurs, discontinue NUCALA.

**Acute Asthma Symptoms or Deteriorating Disease**

NUCALA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

**Opportunistic Infections: Herpes Zoster**

Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

**Reduction of Corticosteroid Dosage**

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

**Parasitic (Helminth) Infection**

Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

**ADVERSE REACTIONS**

Most common adverse reactions (≥5%) in patients receiving NUCALA:

- Severe asthma trials: headache, injection site reaction, back pain, fatigue
- CRSwNP trial: oropharyngeal pain, arthralgia
- EGPA and HES trials (300 mg of NUCALA): no additional adverse reactions were identified to those reported in severe asthma clinical trials

Systemic reactions, including hypersensitivity, occurred in clinical trials in patients receiving NUCALA. Manifestations included rash, pruritus, headache, myalgia, flushing, urticaria, erythema, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, stridor, angioedema, and multifocal skin reaction. A majority of systemic reactions were experienced the day of dosing.

**USE IN SPECIFIC POPULATIONS**

A pregnancy exposure registry monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy. To enroll call 1-877-311-8972 or visit www.mothertobaby.org/asthma.

The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.
**BRIEF SUMMARY**

NUCALA (mepolizumab) for injection, for subcutaneous use

NUCALA (mepolizumab) injection, for subcutaneous use

The following is a brief summary only; see full prescribing information for complete product information.

1 INDICATIONS AND USAGE

1.1 Treatment Maintenance of Severe Asthma

NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. (see Use in Specific Populations (8.4) and Clinical Studies (14.1) of full prescribing information).

1.2 Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps

NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

1.3 Eosinophilic Granulomatosis with Polyangiitis

NUCALA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

1.4 Hypereosinophilic Syndrome

NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

4 CONTRAINDICATIONS

NUCALA is contraindicated in patients with a history of hypersensitivity to mepolizumab or excipients in the formulation [see Warnings and Precautions (5.1) and Description (11) of full prescribing information].

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred following administration of NUCALA. These reactions generally occur within hours of administration, but in some instances can have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, NUCALA should be discontinued [see Contraindications (4)].

5.2 Acute Asthma Symptoms or Deteriorating Disease

NUCALA should not be used to treat acute asthma symptoms or acute exacerbations. Do not use NUCALA to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.

5.3 Opportunistic Infections: Herpes Zoster

Herpes zoster has occurred in subjects receiving NUCALA 100 mg in controlled clinical trials [see Adverse Reactions (6.1)]. Consider vaccination if medically appropriate.

5.4 Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids (ICS) abruptly upon initiation of treatment with NUCALA. Reductions in corticosteroid dosage, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dosage may be associated with systemic withdrawal symptoms and/or unmask previously suppressed systemic corticosteroid therapy.

5.5 Parasitic (Helminth) Infections

Eosinophils may be involved in the immunological response to some helminth infections. Patients with known parasitic infections were excluded from participation in clinical trials. It is unknown if NUCALA will influence a patient’s response against parasitic infections. Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving treatment with NUCALA and do not respond to anti-helminth treatment, discontinue treatment with NUCALA until infection resolves.

6 ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections:

- Hypersensitivity reactions [see Warnings and Precautions (5.1)]
- Opportunistic infections: herpes zoster [see Warnings and Precautions (5.3)]

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.1 Clinical Trials Experience in Severe Asthma

Adult and Adolescent Patients Aged 12 Years and Older

A total of 1,327 patients with severe asthma were evaluated in 3 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks’ duration (Trial 1, NCT01000506; Trial 2, NCT01691521; and Trial 3, NCT01691508). Of these, 1,192 had a history of 2 or more exacerbations in the year prior to enrollment despite regular use of high-dose ICS plus additional controller(s) (Trials 1 and 2), and 135 patients required daily oral corticosteroids (OCS) in addition to regular use of high-dose ICS plus additional controller(s) to maintain asthma control (Trial 3). Of these patients had markers of eosinophilic airway inflammation [see Clinical Studies (14.1) of full prescribing information]. Of the patients enrolled, 59% were female, 85% were White, and ages ranged from 12 to 82 years. Mepolizumab was administered subcutaneously or intravenously once every 4 weeks; 263 patients received NUCALA (mepolizumab 100 mg subcutaneous) for at least 24 weeks. Serious adverse events that occurred in more than 1 patient and in a greater percentage of patients receiving NUCALA 100 mg (n = 263) than placebo (n = 257) included event, herpes zoster (2 patients vs. 0 patients, respectively). Approximately 2% of patients receiving NUCALA 100 mg withdrew from clinical trials due to adverse events compared with 3% of patients receiving placebo.

The incidence of adverse reactions in the first 24 weeks of treatment in the confirmationary efficacy and safety trials (Trials 2 and 3) with NUCALA 100 mg is shown in Table 1.

| Table 1. Adverse Reactions with NUCALA vs Placebo in Patients with Severe Asthma (Trials 2 and 3) |
| --- | --- | --- |
| **Adverse Reaction** | **NUCALA (Mepolizumab 100 mg Subcutaneous)** | **Placebo** |
| **(n = 263)** | **(n = 257)** |
| Headache | 19 | 18 |
| Injection site reaction | 8 | 3 |
| Back pain | 5 | 4 |
| Fatigue | 5 | 4 |
| Urinary tract infection | 3 | 2 |
| Abdominal pain upper | 3 | 2 |
| Puritus | 3 | 2 |
| Eczema | 3 | <1 |
| Muscle spasms | 3 | <1 |

52-Week Trial: Adverse reactions from Trial 1 with 52 weeks of treatment with mepolizumab 75 mg intravenous (IV) (n = 153) or placebo (n = 155) and with ≥3% incidence and more common than placebo and not shown in Table 1 were: abdominal pain, allergic rhinitis, asthma, bronchitis, cystitis, dizziness, dyspnea, ear infection, gastroenteritis, lower respiratory tract infection, musculoskeletal pain, nasal congestion, nasopharyngitis, nausea, pharyngitis, pruritus, rash, toothache, viral infection, viral respiratory tract infection, and vomiting. In addition, 3 cases of herpes zoster occurred in patients receiving mepolizumab 75 mg IV compared with 2 patients in the placebo group.

Systemic Reactions, including Hypersensitivity Reactions: In Trials 1, 2, and 3 described above, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was 3% in the group receiving NUCALA 100 mg and 5% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 1% of patients in the group receiving NUCALA 100 mg and 2% of patients in the placebo group. The most commonly reported manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving NUCALA 100 mg included rash, pruritus, headache, and myalgia. Systemic non-allergic reactions were reported by 2% of patients in the group receiving NUCALA 100 mg and 3% of patients in the placebo group. The most commonly reported manifestations of systemic non-allergic reactions reported in the group receiving NUCALA 100 mg included rash, flushing, and myalgia. A majority of the systemic reactions in patients receiving NUCALA 100 mg (5/7) were experienced on the day of dosing.

Injection Site Reactions: Injection site reactions (e.g., pain, erythema, swelling, itching, burning sensation) occurred at a rate of 3% in patients receiving NUCALA 100 mg compared with 3% in patients receiving placebo.

Long-term Safety: Nine hundred ninety-eight patients received NUCALA 100 mg in ongoing open-label extension studies, during which additional cases of herpes zoster were reported. The overall adverse event profile has been similar to the asthma trials described above. Pediatric Patients Aged 6 to 11 Years

The safety data for NUCALA is based upon 1 open-label clinical trial that enrolled 36 patients with severe asthma aged 6 to 11 years. Patients received 40 mg (for those weighing <40 kg) or 100 mg (for those weighing ≥40 kg) of NUCALA administered subcutaneously once every 4 weeks. Patients received NUCALA for 12 weeks (initial short phase). After a treatment interruption of 8 weeks, 30 patients received NUCALA for a further 52 weeks (long phase). The adverse reaction profile for patients aged 6 to 11 years was similar to that observed in patients aged 12 years and older.

6.2 Clinical Trials Experience in Chronic Rhinosinusitis with Nasal Polyps

A total of 407 patients with CRSwNP were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received NUCALA 100 mg or placebo subcutaneously once every 4 weeks. Patients had recurrent CRSwNP with a history of prior surgery and were on nasal corticosteroids for at least 8 weeks prior to screening [see Clinical Studies (14.2) of full prescribing information]. Of the patients enrolled, 35% were female, 93% were White, and ages ranged from 18 to 62 years. Approximately 2% of patients receiving NUCALA (continued on next page)
6 ADVERSE REACTIONS (cont’d)

100 mg withdrew from study treatment due to adverse events compared with 2% of patients receiving placebo. Table 2 summarizes adverse reactions that occurred in ≥3% of NUCALA-treated patients and more frequently than in patients treated with placebo in the CRSwNP trial.

Table 2. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with CRSwNP

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 206) %</th>
<th>Placebo (n = 201) %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dipharyngeal pain</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>Abdominal Pain Upper</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Nasal dryness</td>
<td>3</td>
<td>&lt;1</td>
</tr>
<tr>
<td>Rash</td>
<td>3</td>
<td>&lt;1</td>
</tr>
</tbody>
</table>

CRSwNP = Chronic Rhinosinusitis with Nasal Polyps.

Systemic Reactions, including Hypersensitivity Reactions

In the 52-week trial, the percentage of patients who experienced systemic (allergic [type I hypersensitivity] and other) reactions was <1% in the group receiving NUCALA 100 mg and <1% in the placebo group. Systemic allergic (type I hypersensitivity) reactions were reported by <1% of patients in the group receiving NUCALA 100 mg and no patients in the placebo group. The manifestations of systemic allergic (type I hypersensitivity) reactions included urticaria, erythema, and rash and 1 of the 3 reactions occurred on the day of dosing. Other systemic reactions were reported by no patients in the group receiving NUCALA 100 mg and <1% of patients in the placebo group.

Injection Site Reactions

Injection site reactions (e.g., erythema, pruritus) occurred at a rate of 2% in patients receiving NUCALA 100 mg compared with <1% in patients receiving placebo.

6.3 Clinical Trials Experience in Eosinophilic Granulomatosis with Polyangiitis

A total of 136 patients with EGPA were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients enrolled had a diagnosis of EGPA for at least 6 months prior to enrollment with a history of relapsing or refractory disease and were on a stable dosage of oral prednisolone or prednisone of greater than or equal to 7.5 mg/day (but not greater than 50 mg/day) for at least 4 weeks prior to enrollment [see Clinical Studies (14.3 of full prescribing information)]. Of the patients enrolled, 50% were female, 92% were White, and ages ranged from 20 to 71 years. No additional adverse reactions were identified to those reported in the severe asthma trials.

Systemic Reactions, including Hypersensitivity Reactions

In the 52-week trial, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was <1% in the group receiving 300 mg of NUCALA and 1% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 4% of patients in the group receiving 300 mg of NUCALA and 1% of patients in the placebo group. The manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving 300 mg of NUCALA included rash, pruritus, flushing, fatigue, hypotension, warm sensation in trunk and neck, cold extremities, dyspnea, and stridor. Systemic non-allergic reactions were reported by 1% (1 patient) in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of systemic non-allergic reactions reported in the group receiving 300 mg of NUCALA was angioedema. Half of the systemic reactions in patients receiving 300 mg of NUCALA (2/4) were experienced on the day of dosing.

Injection Site Reactions

Injection site reactions (e.g., pain, erythema, swelling) occurred at a rate of 15% in patients receiving 300 mg of NUCALA compared with 13% in patients receiving placebo.

6.4 Clinical Trials Experience in Hypereosinophilic Syndrome

A total of 108 adult and adolescent patients aged 12 years and older with HES were evaluated in a randomized, placebo-controlled, multicenter, 32-week treatment trial. Patients with non-hematologic secondary HES or FIP1L1-PDGFRα kinase-positive HES were excluded from the trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients must have been on a stable dose of background HES therapy for the 4 weeks prior to randomization [see Clinical Studies (14.4 of full prescribing information)]. Of the patients enrolled, 55% were female, 93% were White, and ages ranged from 12 to 82 years. No additional adverse reactions were identified to those reported in the severe asthma trials.

Systemic Reactions, including Hypersensitivity Reactions

In the trial, no systemic allergic (type I hypersensitivity) reactions were reported. Other systemic reactions were reported by 1% (2 patients) in the group receiving 300 mg of NUCALA and no patients in the group receiving placebo. The reported manifestation of other systemic reaction was multifocal skin reaction experienced on the day of dosing.

Injection Site Reactions

Injection site reactions (e.g., burning, itching) occurred at a rate of 7% in patients receiving 300 mg of NUCALA compared with 4% in patients receiving placebo.

6.5 Immunogenicity

In adult and adolescent patients with severe asthma receiving NUCALA 100 mg, 15/260 (6%) had detectable anti-mepolizumab antibodies. Neutralizing antibodies were detected in 1 patient with asthma receiving NUCALA 100 mg. Anti-mepolizumab antibodies slightly increased (approximately 20%) the clearance of mepolizumab. There was no evidence of a correlation between anti-mepolizumab antibody titer and change in eosinophil level. The clinical relevance of the presence of anti-mepolizumab antibodies is not known. In the clinical trial of children aged 6 to 11 years with severe asthma receiving NUCALA 40 or 100 mg, 2/35 (6%) had detectable anti-mepolizumab antibodies during the initial short phase of the trial. No children had detectable anti-mepolizumab antibodies during the long phase of the trial.

In patients with CRSwNP receiving NUCALA 100 mg, 6/196 (3%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with CRSwNP.

In patients with EGPA receiving 300 mg of NUCALA, 1/68 (<2%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with EGPA.

In adult and adolescent patients with HES receiving 300 mg of NUCALA, 1/53 (2%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with HES.

The reported frequency of anti-mepolizumab antibodies may underestimate the actual frequency due to lower assay sensitivity in the presence of high drug concentration. The data reflect the percentage of patients whose test results were positive for antibodies to mepolizumab in specific assays. The observed incidence of antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.

6.6 Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postapproval use of NUCALA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to NUCALA or a combination of these factors.

Immune System Disorders

Hypersensitivity reactions, including anaphylaxis.

7 DRUG INTERACTIONS

Formal drug interaction trials have not been performed with NUCALA.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy. Healthcare providers can enroll patients or encourage patients to enroll themselves by calling 1-877-311-8927 or visiting www.motherstobaby.org/asthma.

Risk Summary

The data on pregnancy exposure are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a pregnancy fashion as pregnancy progresses. More, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy. In a prenatal and postnatal development study conducted in cynomolgus monkeys, there was no evidence of fetal harm with IV administration of mepolizumab throughout pregnancy at doses that produced exposures up to approximately 3 times the exposure at the maximum recommended human dose (MRHD) of 300 mg subcutaneous (see Data). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control.

Data

Animal Data: In a prenatal and postnatal development study, pregnant cynomolgus monkeys received mepolizumab from gestation Days 2 to 140 at doses that produced exposures up to approximately 9 times that achieved with the MRHD (on an AUC basis with maternal IV doses up to 100 mg/kg once every 4 weeks). Mepolizumab did not elicit adverse effects on fetal or neonatal growth (including immune function) up to 9 months after birth. Examinations for internal or skeletal malformations were not performed. Mepolizumab crossed the placenta in cynomolgus monkeys. Concentrations of mepolizumab were approximately 2.4 times higher in infants than in mothers up to Day 178 postpartum. Levels of mepolizumab in milk were ≤0.5% of maternal serum concentration.

In a fertility, early embryonic, and embryofetal development study, pregnant CO-1 mice received an analogous antibody, which inhibited the activity of murine interleukin-5 (IL-5), at an IV dose of 50 mg/kg once per week throughout gestation.

(continued on next page)
The analoguous antibody was not teratogenic in mice. Embryofetal development of IL-5-deficient mice has been reported to be generally unaffected relative to wild-type mice.

8.2 Lactation Risk Summary
There is no information regarding the presence of mepolizumab in human milk, the effects on the breastfed infant, or the effects on milk production. However, mepolizumab is a humanized monoclonal antibody (IgG1 kappa), and immunoglobulin G (IgG) is present in human milk in small amounts. Mepolizumab was present in the milk of cynomolgus monkeys postpartum following dosing during pregnancy (see Use in Specific Populations [8.1]). The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NUCALA and any potential adverse effects on the breastfed infant from mepolizumab or from the underlying maternal condition.

8.4 Pediatric Use
Selected Studies
The safety and efficacy of NUCALA for severe asthma, and with an eosinophilic phenotype, have been established in pediatric patients aged 6 years and older. Use of NUCALA in adolescents aged 12 to 17 years is supported by evidence from adequate and well-controlled trials in adults and adolescents. A total of 28 adolescents aged 12 to 17 years with severe asthma were enrolled in the Phase 3 asthma trials. Of these, 25 were enrolled in the 32-week exacerbation trial (Trial 2, NCT01691521) and 3 were in an 8.4-year extension study. Patients had a history of 2 or more exacerbations in the previous year despite regular use of medium- or high-dose ICS plus additional controller(s) with or without OCS and had blood eosinophils of ≥150 cells/mcL at screening or ≥300 cells/mcL within 12 months prior to enrollment. [See Clinical Studies (14.1) of full prescribing information.] Patients had a reduction in the rate of exacerbations that trended in favor of NUCALA. Of the 19 adolescents who received NUCALA, 9 received 100 mg and the mean percent change in AEs was 36% less than that of adults. The safety profile observed in adolescents was generally similar to that of the overall population in the Phase 3 studies [see Adverse Reactions (6.1)].

Use of NUCALA in pediatric patients aged 6 to 11 years with severe asthma, and with an eosinophilic phenotype, is supported by evidence from adequate and well-controlled trials in adults and adolescents with additional pharmacokinetic, pharmacodynamic, and safety data in children aged 6 to 11 years. A single open-label clinical trial (NCT02377427) was conducted in 36 children aged 6 to 11 years (mean age: 8.6 years, 31% female) with severe asthma. Enrollment criteria were the same as for adolescents in the 32-week exacerbation trial (Trial 2). Based upon pharmacokinetic data from this trial, a dose of 40 mg subcutaneous every 4 weeks was determined to have similar exposure to adults and adolescents administered a dose of 100 mg SC [see Clinical Pharmacology (12.3) of full prescribing information]. The effectiveness of NUCALA in pediatric patients aged 6 to 11 years is extrapolated from efficacy in adults and adolescents with support from pharmacokinetic analyses showing similar drug exposure levels for 40 mg administered subcutaneously every 4 weeks in children aged 6 to 11 years compared with adults and adolescents [see Clinical Pharmacology (12.3) of full prescribing information]. The safety profile and pharmacodynamic response observed in this trial for children aged 6 to 11 years were similar to that seen in adults and adolescents [see Adverse Reactions (6.1), Clinical Pharmacology (12.2) of full prescribing information].

The safety and effectiveness in pediatric patients aged younger than 6 years with severe asthma have not been established.

Chronic Rhinosinusitis with Nasal Polyps
The safety and effectiveness in patients aged younger than 18 years with CRSwNP have not been established.

Eosinophilic Granulomatosis with Polyangiitis
The safety and effectiveness in patients aged younger than 18 years with EGPA have not been established.

Hyper eosinophilic Syndrome
The safety and effectiveness of NUCALA for HES have been established in adolescent patients aged 12 years and older. The safety and effectiveness in pediatric patients aged younger than 12 years with HES have not been established. Use of NUCALA for this indication is supported by evidence from an adequate and well-controlled study (NCT02836496) in adults and adolescents and an open-label extension study (NCT03306043). One adolescent received NUCALA during the controlled study and this patient and an additional 3 adolescents received NUCALA during the open-label extension study [see Clinical Studies (14.4) of full prescribing information]. The 1 adolescent treated with NUCALA in the 32-week trial did not have a HES flare or an adverse event reported. All adolescents received 300 mg of NUCALA for 20 weeks in the open-label extension.

8.5 Geriatric Use
Clinical trials of NUCALA did not include sufficient numbers of patients aged 65 years and older that received NUCALA (n = 79) to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. Based on available data, no adjustment of the dosage of NUCALA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.

10 OVERDOSAGE
There is no specific treatment for an overdose with mepolizumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

17 PATIENT COUNSELING INFORMATION
Advisce the patient to read the FDA-approved patient labeling (Patient Information).

Hypersensitivity Reactions
Inform patients that hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred after administration of NUCALA. Instruct patients to contact their physicians if such reactions occur.

Not for Acute Symptoms or Deteriorating Disease
Inform patients that NUCALA does not treat acute asthma symptoms or acute exacerbations. Inform patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.

Opportunistic Infections: Herpes Zoster
Inform patients that herpes zoster infections have occurred in patients receiving NUCALA and where medically appropriate, inform patients that vaccination should be considered.

Reduction of Corticosteroid Dosage
Inform patients to not discontinue systemic or inhaled corticosteroids except under the direct supervision of a physician. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Pregnancy Exposure Registry
Inform women there is a pregnancy exposure registry that monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy and that they can enroll in the Pregnancy Exposure Registry by calling 1-877-311-8972 or by visiting www.motherstobaby.org/asthma [see Use in Specific Populations (8.1)].

Trademarks are owned by or licensed to the GSK group of companies.

Manufactured by GlaxoSmithKline LLC
Philadelphia, PA 19112
U.S. License Number 1727
Distributed by GlaxoSmithKline
Research Triangle Park, NC 27709
©2021 GSK group of companies or its licensor.
Revised: 7/2021
NCL:7BRS
©2021 GSK or licenser.
MPL:RNA210003 December 2021
Produced in USA.
The American College of Chest Physicians (“CHEST”), and its officers, regents, executive committee members, members, related entities, employees, representatives, and other agents (collectively, “CHEST Parties”) are not responsible in any capacity for, do not warrant and expressly disclaim all liability for, any content whatsoever in any CHEST publication or other product (in any medium) and the use or reliance on any such content, all such responsibility being solely that of the authors or the advertisers, as the case may be. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any CHEST publication or other product. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any CHEST Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages. The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or an infrequently employed drug. Some drugs and medical devices presented in this publication may have US Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health-care provider to ascertain the FDA status of each drug or device planned for use in his or her clinical practice. Neither the editors of CHEST Physician nor the Editorial Advisory Board nor the reporting staff contributed to this content. Copyright © 2022 by the American College of Chest Physicians. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means—electronic, mechanical, photocopied, recorded, otherwise—without the prior written permission of the copyright owner.
Choose SEEK as Your Study Resource

For more than 30 years, CHEST SEEK™ Education has been a trusted clinical resource and valuable study tool for chest medicine clinicians preparing for board exams.

Prep for your boards with CHEST SEEK Library, the online subscription option of CHEST SEEK Education. Study on the go with:

- 1,200+ case-based questions in pulmonary, critical care, sleep, and pediatric pulmonary medicine
- Questions based on ABIM exam blueprints
- Timed mock exams with detailed rationales
- More than 300 CME/MOC/CE

Trust CHEST SEEK Education to help you pass your exam.

Get the new CHEST SEEK™ Critical Care Medicine: 32nd Edition, or subscribe to the CHEST SEEK™ Library to start learning.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Contributing Authors</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Comorbidities, Racial Disparities, and Geographic Differences in Asthma</td>
<td>Navitha Ramesh, MD, FCCP</td>
</tr>
<tr>
<td>14</td>
<td>Post-COVID-19 Effects</td>
<td>Viren Kaul, MD, FCCP, FACP</td>
</tr>
<tr>
<td>16</td>
<td>New Pathogens, COVID-19, and Antibiotic Resistance in the Field of Pneumonia</td>
<td>Marcos I. Restrepo, MD, MSc, PhD, FCCP</td>
</tr>
<tr>
<td>19</td>
<td>COPD Characteristics and Health Disparities</td>
<td>Muhammad Adrish, MD, MBA, FCCP</td>
</tr>
<tr>
<td>22</td>
<td>Reducing Tuberculosis Globally and the Impact of COVID-19</td>
<td>Patricio Escalante, MD, MSc, FCCP and Paige K. Marty, MD</td>
</tr>
<tr>
<td>24</td>
<td>New Treatment Pathways for Cystic Fibrosis</td>
<td>David Finklea, MD</td>
</tr>
<tr>
<td>26</td>
<td>Risk Assessment in Pulmonary Arterial Hypertension</td>
<td>Sandeep Sahay, MD, MSc, FCCP, ATSF</td>
</tr>
<tr>
<td>29</td>
<td>Rising Incidence of Bronchiectasis and Associated Burdens</td>
<td>Anne E. O'Donnell, MD, FCCP</td>
</tr>
<tr>
<td>32</td>
<td>ILD: Diagnostic Considerations and Socioeconomic Barriers</td>
<td>Daniel Dilling, MD, FCCP, FACP, FAST</td>
</tr>
<tr>
<td>34</td>
<td>Advances in Lung Cancer Diagnostics and Treatment</td>
<td>Eric S. Edell, MD, FCCP</td>
</tr>
<tr>
<td>37</td>
<td>References</td>
<td></td>
</tr>
</tbody>
</table>

## Common Abbreviations

- ACO: asthma and COPD overlap
- BMI: body mass index
- CF: cystic fibrosis
- COPD: chronic obstructive pulmonary disease
- CT: computed tomography
- FDA: US Food and Drug Administration
- FEV1: forced expiratory volume in the first second
- FVC: forced vital capacity
- GERD: gastroesophageal reflux disease
- HIV: human immunodeficiency virus
- ILD: interstitial lung disease
- OS: overall survival
- PAH: pulmonary arterial hypertension
- PFS: progression-free survival
- TB: tuberculosis
- VHA: Veterans Health Administration
Contributing Authors

The staff at CHEST and the editors of Pulmonology Data Trends 2022 and CHEST Physician would like to thank the following experts for their contributions to this issue.

Muhammad Adrish, MD, MBA, FCCP
Associate Professor
Section of Pulmonary & Critical Care Medicine
Department of Medicine
Baylor College of Medicine
Ben Taub Hospital
Houston, TX

Daniel Dilling, MD, FCCP, FACP, FAST
Medical Director, Lung Transplantation
RML Medical Director, Respiratory Care
Loyola University Medical Center
Maywood, IL

Eric S. Edell, MD, FCCP
Internist and Pulmonologist
Mayo Clinic
Rochester, MN

Patricio Escalante, MD, MSc, FCCP
Associate Professor of Medicine and Consultant
Division of Pulmonary and Critical Care Medicine
Mayo Clinic
Rochester, MN

David Finklea, MD
Associate Professor of Medicine
UT Southwestern Medical Center
Dallas, TX

Viren Kaul, MD, FCCP, FACP
Division Chief, Pulmonary Medicine and Intensivist
Crouse Health
Clinical Assistant Professor of Medicine
Upstate Medical University
Syracuse, NY
Paige Marty, MD
Fellow
Division of Pulmonary and Critical Care Medicine
Mayo Clinic
Rochester, MN

Anne E. O’Donnell, MD, FCCP
Professor of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
The Nehemiah and Naomi Cohen Chair in Pulmonary Disease Research
Georgetown University Medical Center
Washington, DC

Navitha Ramesh, MD, FCCP
Director, Critical Care Medicine Fellowship Program
UPMC Harrisburg
ICU Medical Director
UPMC Community Osteopathic
Pulmonary and Critical Care Medicine
UPMC Central PA
Harrisburg, PA

Marcos I. Restrepo, MD, MSc, PhD, FCCP
Professor of Medicine
Associate Program Director of the Division of Pulmonary Medicine and Critical Care
University of Texas Health Science Center at San Antonio
Director of the Medical Intensive Care Unit
South Texas Veterans Health Care System
San Antonio, TX

Sandeep Sahay, MD, MSc, FCCP, ATSF
Co-Director, CTEPH and PH Programs
Houston Methodist Lung Center
Associate Professor
Division of Pulmonary, Critical Care & Sleep Medicine
Houston Methodist Hospital
Houston, TX
Comorbidities, Racial Disparities, and Geographic Differences in Asthma

Navitha Ramesh, MD, FCCP

Asthma management is becoming increasingly personalized, making it crucial to evaluate the various comorbidities and socioeconomic factors affecting patient care. Asthma is no longer simply understood as the typical allergic asthma requiring treatment with corticosteroids. There is an evolving distinction between allergen-specific T helper 2 (Th2) and non-Th2 asthma. In Th2 asthma, eosinophilic inflammation plays a key role, whereas in non-Th2 asthma, neutrophils are the primary inflammatory cells involved. Asthma masqueraders, such as vocal cord dysfunction, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, etc, must be considered in the differential diagnosis, and asthma comorbidities, such as upper airway cough syndrome, gastroesophageal reflux, depression, and anxiety, have to be actively sought out and managed appropriately.

Racial, socioeconomic, and geographic characteristics are also key patient factors that affect asthma symptoms and control, quality of life, and asthma-related morbidity and mortality. Assessing and understanding the multiple factors that affect each patient is crucial in the optimal management of asthma symptoms, and also preventing exacerbations, which in turn lead to accelerated loss of lung function.

Prevalence of Asthma Comorbidities

Ways Obesity Affects Asthma Symptoms
- Alters chest wall dynamics, affecting ventilation
- Increases airflow limitation
- Worsens airway closure
- Increases airway inflammation from dietary changes

Ways Obesity Affects Asthma Treatment
- Affects biomarkers normally used to identify asthma
- Affects selection of biologics used for treatment
- Pivots focus to treating obesity first
Race, ethnicity, socioeconomic, and geographic factors significantly affect the quality of life and asthma control in most patients. These considerations should be actively reviewed and managed as part of holistic asthma care. A study of 25,659 American adults found that level of education and income had varying impact on the risk of chronic lung disease (CLD), including asthma, in different racial and ethnic groups.

The Impact of Education, Income, and Race and Ethnicity on Risk of CLD[^7,a]

![higher education + higher income = decreased CLD risk]

However, these factors showed less risk improvement for Black and Hispanic patients compared with other races and ethnicities.

[^CLD includes asthma.]

Geographic location has also been shown to affect the incidence of asthma.[^8] Different states and types of communities have varying degrees of asthma prevalence and mortality.

Asthma Age-Adjusted Mortality Rates in Rural vs Urban Areas[^8]

<table>
<thead>
<tr>
<th>Location</th>
<th>Mortality Rate (per 100,000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urban</td>
<td>0.31</td>
</tr>
<tr>
<td>Metropolitan or near-metropolitan</td>
<td>0.33</td>
</tr>
<tr>
<td>Rural</td>
<td>0.00</td>
</tr>
<tr>
<td>Non-metropolitan</td>
<td>0.06</td>
</tr>
</tbody>
</table>

Percentile Rank of Asthma Mortality by State[^8]

- **85th-100th percentile**
  - Average mortality rate: 1.38 per 100,000

- **75th-84th percentile**
  - Average mortality rate: 1.12 per 100,000

- **65th-74th percentile**
  - Average mortality rate: 1.02 per 100,000

- **55th-64th percentile**
  - Average mortality rate: 0.94 per 100,000

- **25th-54th percentile**
  - Average mortality rate: 0.70-0.86 per 100,000

- **0-24th percentile**
  - Average mortality rate: ≤0.11 per 100,000

Adapted from Annals of Allergy, Asthma & Immunology, 128(1):11, Bleecker ER et al, Mapping geographic variability of severe uncontrolled asthma in the United States: Management implications, ©2022, with permission from Elsevier.
Post-COVID-19 Effects

Viren Kaul, MD, FCCP, FACP

Millions of Americans have been affected by the COVID-19 pandemic, with 93.2 million cases as of August 19, 2022.¹ Many of these individuals are experiencing long-term effects after infection with the COVID-19 virus, and various disparities are affecting access to care. Post-acute COVID-19 syndrome is defined as symptoms that persist 4 weeks after the onset of symptoms from COVID-19 infection. Although COVID-19 is primarily a respiratory infection, the long-term effects have been seen in various organ systems. The effects of this condition reach beyond physical health, taking a toll on a patient's economic and psychological well-being. Different racial/ethnic and economic factors also influence likelihood of illness and disease outcomes. Physicians must remain aware of the long-term role these factors will continue to play in patient outcomes.

Long-term Effects of COVID-19²⁻⁵,ᵃ

<table>
<thead>
<tr>
<th>Musculoskeletal</th>
<th>Cardiac</th>
<th>Gastrointestinal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue, muscular weakness and post exertional malaise, joint pain</td>
<td>Palpitations, chest pain, cardiomyopathy</td>
<td>Abdominal pain, altered bowel patterns</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pulmonary</th>
<th>Hematologic</th>
<th>Integumentary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dyspnea, cough, persistent supplemental oxygen requirement</td>
<td>Thromboembolism</td>
<td>Hair loss, rash</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Neurologic</th>
<th>Gastrointestinal</th>
<th>Gynecologic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anxiety, depression, sleep disturbances, PTSD, cognitive disturbances (also known as brain fog), headaches, dizziness, sensory disturbances, altered smell and taste</td>
<td>Abdominal pain, altered bowel patterns</td>
<td>Changes in menstrual cycles</td>
</tr>
</tbody>
</table>

ᵃ This includes effects that persist 4 weeks after symptom onset in both hospitalized and nonhospitalized individuals.

Patient Symptoms and Impairments Remaining 60 Days After Hospitalization⁶

- 12.72% Persistent symptoms related to illness
- 8.96% Breathless walking up stairs
- 7.36% New or worsening symptoms
- 6.48% Shortness of breath
- 6.00% Cough
- 5.12% Continued loss of taste or smell
- 3.52% Difficulty ambulating due to chest pain
- 2.72% New use of breathing machine when asleep
- 2.56% Oxygen use

Post-acute COVID-19 can develop in patients regardless of hospitalization status, but the risk of having long-term symptoms is generally higher among those who were hospitalized.³ A study of 1,250 hospitalized patients looked at symptoms 60 days postdischarge.⁶ Results are demonstrated in the figure to the left.
Post-COVID-19 Burdens and Disparities

Apart from the physical effects of post-acute COVID-19 syndrome, economic and psychological consequences are profound.

### Economic Burden 60 Days After Hospitalization for COVID-19

- **14.32%** Experienced mild financial effects due to health
- **9.92%** Experienced moderate financial effects due to health
- **3.76%** Used up all or most of savings
- **2.32%** Unable to pay for necessities (food, housing)
- **1.36%** Contacted by a collection agency
- **1.28%** Skipped medical care due to cost
- **0.88%** Took less medication due to cost

### Psychological Burden 60 Days After Hospitalization for COVID-19

- **9.04%** Emotions mildly affected due to health
- **9.92%** Emotions moderately affected due to health
- **2.24%** Patients who sought care related to mental health

### Effects of Income, Race/Ethnicity, and Underlying Conditions on Post-COVID-19 Outcomes

Social and economic disparities further affect access to care for those suffering from post-acute COVID-19.

- **14%** of Americans are likely to forgo medical care for COVID-19 and post-acute COVID-19 symptoms due to inability to pay.
- **14%** of Americans are likely to forgo medical care for COVID-19 and post-acute COVID-19 symptoms due to inability to pay.

### People most affected by COVID-19 and post-acute COVID-19 include:

- Individuals with low income
- People of color

### Racially/ethnically diverse patients and individuals with low income have:

- Higher rates of underlying health conditions
- Higher rates of obesity
New Pathogens, COVID-19, and Antibiotic Resistance in the Field of Pneumonia

Marcos I. Restrepo, MD, MSc, PhD, FCCP

Before the onset of the COVID-19 pandemic, researchers in the field of pneumonia were grappling with the increase in the number of pathogens, antimicrobial-resistant strains causing pneumonia, and high mortality in short-term and long-term cases in those with comorbidities and with severe pneumonia.\(^1\,^2\) In 2015, a landmark study identified that the most common pathogens causing community-acquired pneumonia (CAP) were viruses such as rhinovirus and influenza virus, and that the most common bacterial pathogen remained *Streptococcus pneumoniae*.\(^3\) Just as the rest of the world was forced to shift their focus in 2020 because of the pandemic, those of us in the pulmonary space were challenged to understand the impact that COVID-19 would have on treating our patients, particularly those with pneumonia. SARS-CoV-2, the virus that causes COVID-19, in a short time became the leading pathogen causing pneumonia. In addition, severely ill patients with COVID-19 were found to have a higher risk of developing hospital-acquired pneumonia and ventilator-associated pneumonia (VAP). The rate of VAP increased during the pandemic due to several factors, one of them being the time patients with COVID-19 spent on ventilators.\(^3\,^4\)

Now that the pandemic has passed its peak, the field of pneumonia is revisiting earlier concerns—assessment of new pathogens and antibiotic resistance—as well as addressing issues brought to light by the COVID-19 pandemic.

A pre-COVID 19 study of 2,488 patients hospitalized with CAP in the United States investigated the causes of pneumonia and assessed burden of disease by collecting blood and respiratory specimens for pathogens.\(^1\)

Pathogens Detected in Patients With CAP Pre-COVID-19 Pandemic\(^1,a\)

Pathogens were detected in 38% of pneumonia cases. Viruses comprised 23% and bacteria comprised 11% of cases. Viral and bacterial co-infection was seen in 3% of cases.

Incidence of Pneumonia-Related Hospitalization (Cases per 10,000 per year)

\(^{a}\) Participants all >18 years of age.

\(^{a}\) Refers to coronaviruses identified prior to COVID-19.
After the onset of the COVID-19 pandemic, the treatment of viral pneumonia had to be reassessed. COVID-19 had to be taken into consideration when differentiating causes, risk factors, potential therapeutic and preventive interventions, and clinically relevant patient outcomes.

### Viral Pneumonia vs COVID-19 Pneumonia

<table>
<thead>
<tr>
<th>Epidemiology</th>
<th>Viral Pneumonia</th>
<th>COVID-19 Pneumonia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predominant in children &lt;5 years and adults &gt;50 years</td>
<td>Spreads rapidly when CAP viruses peak, having a competitive effect on circulation of other respiratory illnesses</td>
<td>50% of patients with COVID-19 and pneumonia have relevant comorbidities, and 20% have bacterial coinfections at time of ICU admission.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Varieties, but commonly includes:</th>
<th>Fever, cough, dyspnea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild: Fever, cough, shortness of breath, chills, fatigue</td>
<td>Loss of olfactory and gustatory function</td>
<td>GI issues</td>
</tr>
<tr>
<td>Severe: Sepsis, respiratory distress</td>
<td>Headache</td>
<td>Severe: sepsis, respiratory distress</td>
</tr>
</tbody>
</table>

**A study** of 225 patients looked at the incidence of VAP and COVID-19 compared with control patients.

**VAP vs COVID-19 Pneumonia**

- **Higher incidence**
  - COVID-19 patients are 2× more likely to develop VAP than patients without COVID-19

- **More ventilator days**
  - COVID-19 VAP patients: 28/1,000 ventilator days
  - Without COVID-19: 13/1,000 ventilator days

- **Different lung microbiota**
  - COVID-19 patients: Invasive aspergillosis + Herpesviridae activation

**Along with changes** associated with the COVID-19 pandemic, providers will have to deal with issues that were present in the pre-pandemic era and new issues that arose in the post-pandemic era, including newly discovered pathogens, known pathogens, and resistant pathogens.

### Prevalence of Antibiotic-Resistant CAP Deaths Worldwide

- **Global deaths associated with antibiotic-resistant pneumonia:** 4.95 million
- **Regions most affected:** Western sub-Saharan Africa, with 27.3 deaths per 100,000
- **Region least affected:** Australia, with 6.5 deaths per 100,000
Register today for CHEST 2022

CHEST 2022 is back in person in Nashville, Tennessee, October 16-19. Join your friends and colleagues for the one-of-a-kind experience that is CHEST 2022.

What can you expect from CHEST 2022?

- More than 300 educational sessions, including simulation and interactive learning opportunities, addressing the challenges you face in clinical practice
- Original investigation presentations with new, unpublished science
- Networking and social opportunities with experts in your field and from around the world
- New diagnostic and treatment solutions showcased in the CHEST Exhibit Hall
- CME/CE credits and MOC points for hundreds of sessions

Music City is waiting for you!

Register | chestmeeting.chestnet.org
An estimated 16 million Americans have been diagnosed with chronic obstructive pulmonary disease (COPD), which is the fourth leading cause of death in the United States. Many of the health disparities in COPD diagnosis and care stem from the usual suspects: racial and ethnic barriers, lack of access, and socioeconomic burdens. Overall, COPD affects about 6.1% of Black Americans and 6.3% of non-Hispanic White Americans.

However, while lower education and income are generally associated with poorer outcomes, Black and Hispanic patients with COPD who are highly educated and who have high incomes still show worse health status than their White counterparts. Incidence of COPD also varies by region, with rural states such as Alabama, Arkansas, and Kentucky having some of the highest rates. These inequalities support the need for continued research to address the varying health behaviors, comorbidities, and systemic barriers causing disparities for Black and Hispanic patients with COPD.

**Impact of Race and Socioeconomic Status on COPD Severity Scores**

White patients, college degree or higher, and high income (>$80,000) are reference points. Higher scores reflect poorer status.

**Factors Contributing to Worse Health Outcomes**

Among Black and Hispanic patients – even those with higher education and income levels – factors may include:

- Increased cigarette and e-cigarette use
- Increased alcohol use
- Poorer diet
- Increased suicide attempts
- Increased obesity
- Residential segregation
- Extra costs of upward social mobility

Black race was associated with greater disease severity. When adjusting for socioeconomic status, this difference was mostly due to higher rates of comorbidities, smoking history, and elevated BMI.

Lower education and income were associated with increasingly poor health status.
A study of Black and Hispanic patients with airway obstruction looked at the effects of race and gender on the likelihood of COPD diagnosis.6

**Black patients with airway obstruction were…**

- **Younger**
  - Black: 54.8 years
  - Hispanic: 62.2 years

- **More likely to be male**
  - Black: 86%
  - Hispanic: 53%

- **More likely to be current smokers**
  - Black: 79.5%
  - Hispanic: 38.3%

- **Less likely to have received a prior diagnosis of COPD**
  - Black: 79.5%
  - Hispanic: 44% undiagnosed

**Severity of Undiagnosed COPD in Black and Non-Hispanic White Patients**

GOLD grades range from 1 (mild) to 4 (very severe). GOLD, Global Initiative for Chronic Obstructive Lung Disease.

<table>
<thead>
<tr>
<th>GOLD Grade</th>
<th>Black</th>
<th>Non-Hispanic White</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>13.0%</td>
<td>50.5%</td>
</tr>
<tr>
<td>2</td>
<td>54.5%</td>
<td>31.2%</td>
</tr>
<tr>
<td>3</td>
<td>1.3%</td>
<td>8.1%</td>
</tr>
<tr>
<td>4</td>
<td>0.7%</td>
<td>40.7%</td>
</tr>
</tbody>
</table>

**Regional Distribution of Patients with COPD Across the United States**

- **Northeast**: 15.2%
- **Midwest**: 24.7%
- **South**: 38.6%
- **West**: 21.5%

**Prevalence of COPD Based on Urban/Rural Status**

- **Urban – Poor**: 9.0%
  - vs Non-poor: 6.1%
- **Suburban – Poor**: 11.0%
  - vs Non-poor: 6.7%
- **Medium Metro – Poor**: 11.1%
  - vs Non-poor: 8.0%
- **Small Metro – Poor**: 10.9%
  - vs Non-poor: 9.5%
- **Rural – Poor**: 15.7%
  - vs Non-poor: 12.0%
Estimated Worldwide Prevalence of Asthma-COPD Overlap in Patients With COPD

<table>
<thead>
<tr>
<th>Region</th>
<th>Prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2%</td>
<td>41.9%</td>
</tr>
<tr>
<td>4.7-7.7%</td>
<td>12.6-41.4%</td>
</tr>
<tr>
<td>0.8-5.9%</td>
<td>16.4-55.2%</td>
</tr>
<tr>
<td>2.5-8.4%</td>
<td>17.4-18.3%</td>
</tr>
<tr>
<td>2.6-9.1%</td>
<td>18.8-28.9%</td>
</tr>
<tr>
<td>2.7%</td>
<td>20.8-55.7%</td>
</tr>
<tr>
<td>11.8%</td>
<td></td>
</tr>
<tr>
<td>13.0%</td>
<td></td>
</tr>
<tr>
<td>4.4%</td>
<td>53.5%</td>
</tr>
</tbody>
</table>

Identifying At-Risk Patients

**Symptoms**

- **Chronic cough and phlegm**: 4× higher incidence of COPD vs those without symptoms
- **Chronic productive cough**: 3× higher incidence of COPD in smokers vs nonsmokers
- **Chronic bronchitis**: Higher risk of airflow obstruction, Greater FEV₁ decline, Higher mortality among smokers
- **Any respiratory symptoms**: Decline in FEV₁, Decline in FVC, Airflow obstruction
Reducing Tuberculosis Globally and the Impact of COVID-19

Patricio Escalante, MD, MSc, FCCP and Paige K. Marty, MD

In 2020, more than 1.5 million people died of tuberculosis (TB), and 10 million people contracted the illness globally.¹ The World Health Organization (WHO) End TB Strategy aimed to reduce the number of deaths by 35% between 2015 and 2020, yet reduction was just 9.2% (one-quarter of the goal) during this period.²

TB remains the 13th leading cause of death worldwide and is second only to COVID-19 in terms of pathogen-related mortality.¹ In fact, due to a significant shift in attention and resources to COVID-19, the death toll for TB has risen for the first time in over a decade.²,³ This disruption has led experts to take a closer look at the characteristics and disparities surrounding those deaths. Areas of focus are the health and socioeconomic consequences of TB and COVID-19 as they relate to a TB-related deaths and biosocial inequities in access to essential care. These factors are predicted to lead to a 20% increase in TB death in high-burden countries.⁴,⁵

TB management needs to improve at the clinical and public health levels. Adults and children exposed to patients with TB or subclinical pulmonary TB, often with their own conditions that affect their immune response, are at a particularly high risk for acquiring latent tuberculosis infection (LTBI) and developing active TB. Thus, improved prevention, screening, and treatment strategies are urgently needed.⁶-⁸ While efforts are ongoing to improve TB vaccines, recent discoveries and technical developments have shown the potential to substantially improve TB prevention efforts through rapid and accurate diagnostic management and innovation that can benefit people at risk of developing TB in resource-limited settings.⁹-¹¹ Despite this recent progress, multiple challenges remain, including suboptimal investment in global TB control efforts and innovation, increasing rates of drug-resistant TB, as well as lack of and unequal access to services to patients and individuals in need in many countries across the world.¹,³,¹¹

---

**Risk Factors for Developing TB**¹

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Risk Increase</th>
<th>New Attributable Cases in 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malnutrition</td>
<td>3.0x</td>
<td>1.9 million new TB cases</td>
</tr>
<tr>
<td>Alcohol use disorder</td>
<td>3.3x</td>
<td>0.74 million new TB cases</td>
</tr>
<tr>
<td>Smoking</td>
<td>1.6x</td>
<td>0.73 million new TB cases</td>
</tr>
<tr>
<td>HIV</td>
<td>18x</td>
<td>215,000 TB-related deaths</td>
</tr>
</tbody>
</table>

86% of New TB Cases in 2020 Occurred in Regions With High TB Burden²

- 25% Africa
- 43% Southeast Asia
- 18% Western Pacific Region

Published by WHO, 2021
Comorbidities and Social Determinants of Health Leading to Increased Vulnerability in TB and COVID-19 Infection¹²,¹³

Chronic lung diseases
Immunocompromised state
Cancer
Type 2 diabetes mellitus
Poverty
Malnutrition
Over age 60
HIV co-infection

Overall, mortality risk is 2.17x higher for people with TB vs those without.

For patients with TB, the chance of recovery is 25% lower in patients who also have COVID-19.¹⁴

Characteristics and Implications of TB and COVID-19¹²

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>TB¹²</th>
<th>COVID-19¹²</th>
<th>Impact of COVID-19 on TB¹²,¹⁵,¹⁶</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability of effective vaccine</td>
<td>Yes*</td>
<td>Yes*</td>
<td>Global TB deaths predicted to increase by 20%.</td>
</tr>
<tr>
<td>Availability of rapid diagnostics</td>
<td>Yes</td>
<td>Yes</td>
<td>$100 billion invested in COVID-19 vaccines vs barely $100 million invested per year for TB.</td>
</tr>
<tr>
<td>Availability of cure</td>
<td>Yes</td>
<td>Yes</td>
<td>15% reduction in the number of people treated for drug-resistant TB.</td>
</tr>
<tr>
<td>Limitations of current treatments</td>
<td>An increased prevalence of drug resistance to available antibiotics and prolonged treatment regimens require public health resources to administer and monitor.</td>
<td>New SARS-CoV-2 variants have challenged the effectiveness of various monoclonal antibodies, but antivirals and anti-inflammatory therapies remain effective.⁵</td>
<td>21% decrease in patients receiving preventive TB treatment.</td>
</tr>
<tr>
<td>Policy development</td>
<td>Slow</td>
<td>Rapid</td>
<td>$500 million decrease in global TB spending from 2019 to 2020.</td>
</tr>
<tr>
<td>Potential for stigma</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Economic impact</td>
<td>Large (slow)</td>
<td>Large (rapid)</td>
<td></td>
</tr>
<tr>
<td>Stress on health systems</td>
<td>Large (slow)</td>
<td>Large (rapid)</td>
<td></td>
</tr>
</tbody>
</table>

¹ BCG vaccination is effective in preventing meningeal and disseminated TB in children but mostly ineffective in preventing pulmonary TB in adults.
² Updated due to availability of effective COVID-19 vaccine, after this article was published.
³ Available treatment can reduce disease progression, morbidity, and mortality.

For patients with TB, the chance of recovery is 25% lower in patients who also have COVID-19.¹⁴
New Treatment Pathways for Cystic Fibrosis

David Finklea, MD

Cystic fibrosis is a deadly genetic disorder, affecting 80,000 people worldwide. The disorder is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene codes for a protein that creates epithelial channels in the respiratory track, along with other organs. Mutations in this gene can create improper ion balance, leading to thick and sticky mucus that blocks airways in the lungs and contributes to infections in people with CF (pwCF).

Currently, there is no cure for cystic fibrosis, but newer research is looking into modulating the CFTR gene from multiple pathways by repairing, restoring, or replacing the CFTR protein. At this point, CFTR modulators are the most promising new treatments for cystic fibrosis.

CFTR modulators involve repairing the CFTR protein made from this gene. To qualify for treatment with this class of drugs, people with cystic fibrosis need to have certain CFTR mutations. Fortunately, approximately 90% of pwCF qualify for CFTR modulators. Due to this, the Cystic Fibrosis Foundation is working on finding alternative therapies that are listed below.

Different Treatment Pathways for Cystic Fibrosis

Potential Pathways
- Repair CFTR protein.
- Restore CFTR protein.
- Fix or replace the CFTR gene.

Repair CFTR Protein
- CFTR modulators
  Four are currently FDA-approved; more are in the clinical trial pipeline.

Restore CFTR Protein
- RNA therapy
- Antisense oligonucleotide therapy
  More work is needed.

Fix or Replace CFTR Gene
- Gene editing
- Gene transfer
  Challenges remain.

Elexacaftor/tezacaftor/ivacaftor (ETI) vs Placebo

ETI is a CFTR modulator which, compared with placebo, has shown significant improvement in lung function and fewer pulmonary exacerbations.

- Estimated annualized pulmonary exacerbation rate:
  - 0.37 (ETI) vs 0.98 (placebo)
  - 63% lower

- Change in percentage of predicted FEV₁ at week 24:
  - 13.9 vs -0.4
  - 14.3 mean treatment difference

- Change in CFQ-R respiratory domain score at week 24:
  - 17.5 vs -2.7
  - 20.2-point difference (minimum clinically significant difference is 4)

- Improvement in BMI at week 24:
  - 1.13 vs 0.09
  - 1.04 mean treatment difference
Unfortunately, not all pwCF can receive CFTR modulators. This is most pronounced based on racial and ethnic backgrounds. Because of this, the Cystic Fibrosis Foundation is actively working to provide therapies to overcome this disparity.

**Race and CFTR Modulators**

Women with cystic fibrosis taking ETI have experienced increased fertility and increased unexpected pregnancies. In a small study of women with cystic fibrosis (n=201), 14 (6.9%) patients conceived after ETI initiation.

**Rate of Qualification for CFTR Modulators by Race/Ethnicity**

- **92.4%** of non-Hispanic White patients
- **75.6%** of Hispanic patients
- **69.7%** of Black patients

**Pregnancy and CFTR Modulators**

CFTR modulators are known to improve clinical symptoms. One way this is demonstrated is through increased pregnancy rates in women after taking CFTR modulators. Alterations to cervical mucus viscosity and pH, secondary amenorrhea caused by stress, chronic illness, and/or inflammation, and low BMI are all speculated contributing factors to subfertility in patients with cystic fibrosis.

**Infertility Rates**

Women with cystic fibrosis taking ETI have experienced increased fertility and increased unexpected pregnancies. In a small study of women with cystic fibrosis (n=201), 14 (6.9%) patients conceived after ETI initiation. 50% of these women were not trying to conceive (using contraceptive method).

**Increased Number of Pregnancies Due to CFTR Modulators**

More women are becoming pregnant in the last decade as CFTR modulators are becoming widely available to all pwCF. In 2019, ETI was approved by the FDA. Effects of CFTR modulators on the fetus are currently unknown. More research is being done in this area. CFTR modulators are a step in the right direction in achieving the Cystic Fibrosis Foundation’s goal to have CF stand for CURE FOUND for all, but there is more work to be done.
Risk Assessment in Pulmonary Arterial Hypertension

Sandeep Sahay, MD, MSc, FCCP, ATSF

Properly assessing risk level at the time of diagnosis and follow up is crucial for understanding each patient’s case, identifying modifiable barriers and the most appropriate treatment options, and, ultimately, optimizing survival outcomes for pulmonary arterial hypertension (PAH). Despite the variety of risk assessment tools and electronic medical records at clinicians’ disposal, these resources remain underutilized.1

A survey, designed by CHEST’s Pulmonary Vascular Disease section of the Pulmonary Vascular and Cardiovascular Network, asked members to share insight into their use and perceptions of PAH risk assessment tools in clinical practice. Although the ability of proper risk assessment to greatly improve patient care has been demonstrated in the literature and is recommended by most clinical guidelines, the results of this survey revealed that more than one-third of specialists were not using guideline-recommended risk tools to assess PAH, and only 7% reported that risk assessment tools impacted their treatment decision in new patient care and evaluation.1-4

There is a lack of consensus in patterns of risk tool use among physicians, with 58% reporting that they use more than one tool. In addition to continued clinical research to support the use of available tools and the development of new ones, clinician education programs can help increase the positive impact that risk assessment has on patient survival and other outcomes.1,5

Who is using risk assessment tools for the stratification of PAH?

Users vs Non-users1

- 63% Clinicians using PAH risk stratification tools in practice
- 24% Clinicians not using PAH risk stratification tools in practice
- 13% No response

Use of PAH Risk Assessment Tools by Practice Setting1

- 80.0% Academic center
- 54.5% Community-based hospital
- 66.7% VHA or military health system
- 71.4% Others

Specialists Using PAH Risk Assessment Tools1

- 70.4% Pulmonary medicine
- 92.9% Cardiology
- 50.0% Internal medicine
Another study evaluated the results of PAH risk assessment tools compared with physicians' risk assessment based on clinical judgment. Researchers found substantial incongruencies. Stratification based on clinical judgment resulted in both underestimation and overestimation of risk compared with assessments using objective methods.2

Initial Classification by Physician Assessment Compared With Objective Risk Assessment Tool2,a

<table>
<thead>
<tr>
<th>Risk Assessment Tool</th>
<th>Initial Classification</th>
<th>After Objective Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low risk</td>
<td>Intermediate risk</td>
</tr>
<tr>
<td>Physician Assessment</td>
<td>39%</td>
<td>48%</td>
</tr>
<tr>
<td>Objective Risk</td>
<td>13%-61%</td>
<td>31%-39%</td>
</tr>
</tbody>
</table>

After objective classification:
- Low risk: 13%-61%
- Intermediate risk: 31%-39%
- High risk: 14%-48%

Comorbidities Associated With Risk Assessment Incongruencies2

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Risk Assessment</th>
<th>With Comorbidity</th>
<th>Without Comorbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic Hypertension</td>
<td>35%</td>
<td>27%</td>
<td>27%</td>
</tr>
<tr>
<td>Autoimmune Disease</td>
<td>33%</td>
<td>24%</td>
<td>24%</td>
</tr>
<tr>
<td>Obesity</td>
<td>29%</td>
<td>38%</td>
<td>38%</td>
</tr>
</tbody>
</table>

*Risk was assessed objectively using the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), French Pulmonary Hypertension Registry (FPHR), and the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL 2.0) tools.
Help Us Drive Better Patient Outcomes

A patient’s experience and compliance throughout treatment can be set in just 5 minutes.

The First 5 Minutes™ program from CHEST will provide clinicians with the tools needed to establish trust and rapport with their patients, even under time constraints.

You can help us give hope to patients everywhere by supporting this program.

Big or small, your donation matters. Make your gift today.

DONATE

foundation.chestnet.org/ways-to-give/fundraising-appeal
Bronchiectasis has historically been considered an uncommon and often neglected disease in respiratory medicine. Although bronchiectasis was previously thought to be an orphan disease, its incidence and prevalence have been on the rise since the early 2000s, and the disease is now estimated to affect between 0.25% and 0.5% of adults. This observed increase can be attributed at least partially to two key factors: growing use of CT scanning has allowed for higher detection of abnormal airways, and the global population is aging. Bronchiectasis is more common in elderly people, and the number of persons aged 65 and older is estimated to double by 2050.

As bronchiectasis has become more widely recognized as a serious and prevalent condition, the need for clinical research and consensus in this area has also increased. In 2017, the European Respiratory Society released the first international guidelines that provide recommendations for reducing exacerbations, symptoms, and risk for future complications, while improving quality of life.

In 2022, clinicians are more equipped than ever to identify and treat bronchiectasis. However, the immense comorbidity and economic burdens that accompany this disease will continue to present challenges. Using a shared decision-making approach is important to understand and address each patient’s unique goals and concerns and, thus, optimize their health outcomes.
Increased resource use leads to $5,681 more in costs for patients with bronchiectasis compared with patients without bronchiectasis.
Increasing Economic Burden in the United States\(^1\)

Mean total annual costs for bronchiectasis (per patient)

Bronchiectasis Symptoms, Untreated Outcomes, and Management Options\(^1\)

### Symptoms
- Chronic cough
- Sputum production
- Exacerbations

### Untreated Outcomes
- Presented significant morbidity
- Reduced physical performance
- Impacted health-related quality of life

### Management Options
- Airway clearance therapies
- Physiotherapy/exercise
- Antibiotic therapy
- Anti-inflammatory treatment
- Hospitalization with antibiotic treatment
When navigating the multiple layers of interstitial lung disease (ILD), new American Thoracic Society (ATS) guidelines recommend a diagnostic approach through the lenses of radiologic progression, worsening symptoms, and physiologic progression. An interdisciplinary approach to diagnosis and treatment of patients with ILDs is key for informed decision-making and for optimizing outcomes. Also, guidelines presented by CHEST on ILD dive deeper, addressing diagnostic decision-making, evaluation, gaps, challenges, and risk management failures, as they specifically pertain to hypersensitivity pneumonitis.

Radiologists, pathologists, and pulmonologists look at newer methods of ILD diagnosis—such as transbronchial lung cryobiopsy and genomic classifiers—from a systemic point of view and utilize artificial intelligence to explore new techniques that may be beneficial to patients. Additionally, characteristics associated with health disparities, inequities, social determinants, and neighborhood-level disadvantages all affect patients and show clear differences in access to care in the United States.

Given the nature of ILD, patients may experience disease progression culminating in the need for lung transplantation or in death from their disease. Ensuring proper care for patients with ILD is an urgent priority for pulmonologists. With further research and, hopefully, with changes to how we approach ILD care in society, our goal is to eradicate these socioeconomic disparities, so patients receive proper diagnosis and care.

CT Scan Features and ATS Diagnostic Considerations for UIP Diagnosis in Patients With IPF

CT Scan Features for UIP Patterns

**Definite**
- Honeycombing
- Irregular thickening of interlobular septa
- Superimposed reticular pattern, mild GGO
- Pulmonary ossification

**Probable**
- Reticular pattern with bronchiectasis traction
- Mild GGO
- No appearance of subpleural sparing

**Indeterminate**
- Lung fibrosis features show no specific etiology

GGO, ground glass opacity; IPF, idiopathic pulmonary fibrosis; UIP, usual interstitial pneumonia

Alternative Diagnostic Considerations
- Cysts
- Mosaic attenuation or three-density sign
- Predominant GGO
- Profuse centrilobular micronodules
- Nodules
- Pleural plaques
- Dilated esophagus
Disparities in Care and Outcomes in US Patients With Fibrosing ILD

Among those living in the most deprived neighborhoods:

- Death rates are 51% higher compared with least deprived areas.
- Patients are 64% less likely to have lung transplants.
- 51% higher death rates compared with least deprived areas.
- 64% less likely to have lung transplants.

By comparison, no such disparities were seen in comparable cohorts of Canadian patients.

>40% of patients with idiopathic pulmonary fibrosis have not seen a pulmonologist.

Average out-of-pocket drug costs >$4,700 per year.

High costs can lead to a ~70% increase in Medicare beneficiaries going >30 days without filling their prescriptions.

Cryobiopsy/Cryotransbronchial Biopsy vs Forceps Biopsy/Forceps Transbronchial Biopsy

<table>
<thead>
<tr>
<th>Specimen area</th>
<th>CB/CTBB</th>
<th>FB/FTBB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collects larger samples (standard mean difference 1.21)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diagnostic (IC) rate</th>
<th>CB/CTBB</th>
<th>FB/FTBB</th>
</tr>
</thead>
<tbody>
<tr>
<td>91.67% (risk ratio 1.36)</td>
<td>72.13%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bleeding severity</th>
<th>CB/CTBB</th>
<th>FB/FTBB</th>
</tr>
</thead>
<tbody>
<tr>
<td>23.76% in this analysis, one of three studies that examined bleeding found significantly more bleeding with CB/CTBB.</td>
<td>20.83%</td>
<td></td>
</tr>
</tbody>
</table>
Advances in Lung Cancer Diagnostics and Treatment

Eric S. Edell, MD, FCCP

Lung cancer remains the leading cause of cancer death worldwide, killing about three times as many men and women as prostate and breast cancer, respectively. The introduction of targeted therapy and immunotherapy has markedly increased survival rates over the last decade.1 Robotic technologies at both the diagnostic and treatment stages have shown promise for the management of lung cancer in these patients.2,3 Smoking rates have also been steadily declining in the United States—from 20.9% in 2005 to 12.5% in 2020.4

Based on these combined factors, the fact that lung cancer continues to outpace others in terms of cancer incidence and mortality may not be entirely due to a lack of innovation or improvement in health behaviors. A remaining piece of the puzzle might be sufficient uptake in screening among high-risk adults. Identifying lung cancer before it progresses beyond stage I significantly improves 5-year survival rates, but few patients are diagnosed that early.5 The US Preventive Services Task Force, CHEST, and other organizations updated screening recommendations in 2021 to include earlier low-dose computed tomography (CT) scan screening (age 50 instead of 55) and to include people with even less smoking history (from 30 pack-years to 20).6,7 Before these updates were made, it was estimated that about 4.5% of at-risk adults (aged 55-80 years) received a CT scan within the last year.8

We have yet to see what impact these guidelines will have in practice. Without physician awareness and patient education, it is likely that screening rates and the number of cases caught in early stages will stay low—despite the growing number of tools at our disposal.

Incidence and Mortality Steadily Decreasing1

Since 1990, mortality has decreased by 56% in men.
Since 2002, mortality has decreased by 32% in women.
Between 2009 and 2018, incidence decreased by 2.8% per year in men and by 1.4% per year in women.

Immunotherapy and Targeted Therapy Survival Benefits9-11

Immunotherapy9
Predictors of significantly prolonged progression-free survival (PFS) and overall survival (OS):
• <3 metastasis sites
• Grade 2 immune-related adverse event
• Response to treatment
• Age <65 (OS only)

Neoadjuvant Immunotherapy + Chemotherapy10
Shows significant improvements vs chemotherapy alone:
• Event-free survival: 31.6 months vs 20.8 months
• Patients with complete response: 24.0% vs 2.2%

Targeted Therapy11
Significantly longer disease-free survival compared with placebo at 24 months—90% vs 44%
Compared with muscle-sparing thoracotomy (OPEN), intervention with robotic surgery (RATS) has shown significant improvement in global health status scores and other quality of life measures at hospital discharge and 12-month follow-up.²

### Global Health Status Scores

<table>
<thead>
<tr>
<th></th>
<th>RATS</th>
<th>OPEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>PreOp</td>
<td>83.3</td>
<td>93.3</td>
</tr>
<tr>
<td>Hospital discharge</td>
<td>75.0</td>
<td>67.7</td>
</tr>
<tr>
<td>2-Week visit</td>
<td>66.7</td>
<td>54.2</td>
</tr>
<tr>
<td>6-Month visit</td>
<td>83.3</td>
<td>75.0</td>
</tr>
<tr>
<td>12-Month visit</td>
<td>83.3</td>
<td>62.5</td>
</tr>
</tbody>
</table>

### Significant Differences in Disease Severity Scores

**At hospital discharge**

<table>
<thead>
<tr>
<th></th>
<th>RATS</th>
<th>OPEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung cancer scale</td>
<td>11.1</td>
<td>15.9</td>
</tr>
<tr>
<td>Thoracic pain LC13</td>
<td>30.0 ±12.2</td>
<td>47.6 ±26.5</td>
</tr>
</tbody>
</table>

**At 12-month visit**

<table>
<thead>
<tr>
<th></th>
<th>RATS</th>
<th>OPEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung cancer scale</td>
<td>8.3</td>
<td>13.9</td>
</tr>
<tr>
<td>Thoracic pain LC13</td>
<td>15.8 ±18.0</td>
<td>28.3 ±22.5</td>
</tr>
</tbody>
</table>

Robotic-assisted bronchoscopy has shown promising results in lesion localization, as well as safety, that is comparable to conventional bronchoscopy methods.³

- **Successful lesion localization:** 96.2%
  - Time to median lesion confirmation: 13 minutes
- **Pneumothorax occurred:** 3.7%
  - No other significant adverse events noted
- **Diagnostic yield:** 74% vs 40% to 60% for alternative bronchoscopy approaches
  - Diagnostic yield for eccentric lesions: 70% vs 30% to 40% with alternative bronchoscopy approaches in this population

Timely Low-Dose CT Scan Screening Leads to Improved Outcomes⁵

- Relative reduction in mortality at 10 years
  - Surgical resection is 3x more prevalent in patients who were screened early vs those who were not.

- 26% vs 39%
Ready to Go Hands-on?

Keep your knowledge and skill set up to date with our expert-led continuing medical education courses. Get all the relevant updates, plus the irreplaceable benefits of hands-on instruction and practice.

2022 COURSES
CHEST Global Headquarters | Glenview, IL

SEPTEMBER 22-24
Comprehensive Bronchoscopy With Endobronchial Ultrasound

NOVEMBER 10-11
Critical Care Ultrasound: Integration Into Clinical Practice

NOVEMBER 18
Comprehensive Pleural Procedures With Cadavers

NOVEMBER 19
Advanced Airway Management With Cadavers

DECEMBER 1-2
Ultrasonography: Essentials in Critical Care

DECEMBER 9-10
Extracorporeal Support for Respiratory and Cardiac Failure in Adults

DECEMBER 6, 13, 15
Virtual Advanced Critical Care Echocardiography Board Review Course

LEARN MORE AND REGISTER
References

Comorbidities, Racial Disparities, and Geographic Differences in Asthma


New Pathogens, COVID-19, and Antibiotic Resistance in the Field of Pneumonia


COPD Characteristics and Health Disparities


Post-COVID-19 Effects


SEPTEMBER 2022 • A SUPPLEMENT TO CHEST PHYSICIAN • 37
Reducing Tuberculosis Globally and the Impact of COVID-19


New Treatment Pathways for Cystic Fibrosis


Risk Assessment in Pulmonary Arterial Hypertension


Rising Incidence of Bronchiectasis and Associated Burdens


**ILD: Diagnostic Considerations and Socioeconomic Barriers**


**Advances in Lung Cancer Diagnostics and Treatment**


*PULMONOLOGY DATA TRENDS 2022*
New data on Nodify Lung® Nodule Risk Assessment testing from the ORACLE clinical utility study to be presented at CHEST 2022.